Skip to main content
    S

    Surgery Partners Inc (SGRY)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $14.55
    +0.31 (+2.18%)

    Market Cap: $1.86B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    +0.01%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.12
    Range$0.10 - $0.16
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.13-5.8%
    60d ago$0.13-8.0%
    30d ago$0.13-4.7%
    7d ago$0.120.0%
    Current$0.12
    Revenue Consensus
    $796M
    Range$719M - $825M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.30
    Range$0.19 - $0.42
    4 analysts
    Revenue Consensus
    $698M
    Range$651M - $726M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.30---
    Sep 26EST
    		-$0.12---
    Jun 26
    Reported Aug 10
    		$0.07$-0.03+333.33%Beat-58.8%
    Mar 26
    Reported May 5
    		$-0.03N/A+78.57%Beat-175.0%
    Dec 25
    Reported Mar 2
    		$0.12N/A-60.50%Miss-72.7%
    Sep 25
    Reported Nov 10
    		$0.13$0.16-18.75%Miss-31.6%
    Jun 25
    Reported Aug 5
    		$0.17$0.14+21.43%Beat-19.0%
    Mar 25
    Reported May 12
    		$0.04$0.05-20.00%Miss-60.0%
    Dec 24
    Reported Mar 3
    		$0.44$0.38+16.74%Beat+0.0%
    Sep 24
    Reported Nov 12
    		$0.19$0.26-26.92%Miss+0.0%
    Jun 24
    Reported Aug 6
    		$0.21$0.20+5.00%Beat-25.0%
    Mar 24
    Reported May 7
    		$0.10$0.08+25.00%Beat+25.0%
    Dec 23
    Reported Feb 26
    		$0.44$0.38+15.79%Beat+63.0%
    Sep 23
    Reported Nov 7
    		$0.19$0.15+26.67%Beat+1050.0%
    Jun 23
    Reported Aug 1
    		$0.28$0.08+250.00%Beat+1033.3%
    Mar 23
    Reported May 1
    		$0.08$0.01+700.00%Beat+188.9%
    Dec 22
    Reported Mar 1
    		$0.27$0.18+50.00%Beat+17.4%
    Sep 22
    Reported Nov 8
    		$-0.02N/A-140.00%Miss+60.0%
    Jun 22
    Reported Aug 2
    		$-0.03$-0.02-50.00%Miss-1775.0%
    Mar 22
    Reported May 3
    		$-0.09$-0.06-50.00%Miss+70.0%
    Dec 21
    Reported Feb 28
    		$0.23$0.19+21.05%Beat+155.6%
    Sep 21
    Reported Nov 2
    		$-0.05$-0.10+50.00%Beat+90.6%
    Jun 21
    Reported Aug 4
    		$-0.00N/A+98.93%Beat+99.7%
    Mar 21
    Reported May 5
    		$-0.30$-0.39+23.08%Beat+11.8%
    Dec 20
    Reported Mar 10
    		$0.09$0.02+350.00%Beat-35.7%
    Sep 20
    Reported Nov 4
    		$-0.53$-0.34-55.88%Miss-89.3%
    Jun 20
    Reported Aug 5
    		$-0.48$-0.74+35.14%Beat-65.5%
    Mar 20
    Reported May 11
    		$-0.34$-0.48+29.17%Beat+19.0%
    Dec 19
    Reported Mar 5
    		$0.14$0.17-17.65%Miss+182.4%
    Sep 19
    Reported Nov 5
    		$-0.28$-0.18-55.56%Miss-47.4%
    Jun 19
    Reported Aug 7
    		$-0.29$-0.15-93.33%Miss-61.1%
    Mar 19
    Reported May 8
    		$-0.42$-0.25-68.00%Miss-61.5%
    Dec 18
    Reported Mar 13
    		$-0.17$0.12-241.67%Miss+71.2%
    Sep 18
    Reported Nov 7
    		$-0.19$-0.08-137.50%Miss-850.0%
    Jun 18
    Reported Aug 9
    		$-0.18$-0.15-20.00%Miss-1700.0%
    Mar 18
    Reported May 9
    		$-0.26$-0.18-44.44%Miss-750.0%
    Dec 17
    Reported Mar 1
    		$-0.59$0.07-942.86%Miss-410.5%
    Sep 17
    Reported Nov 8
    		$-0.02N/A+66.67%Beat-
    Jun 17
    Reported Aug 8
    		$-0.01N/A-105.26%Miss-
    Mar 17
    Reported May 9
    		$0.04$0.07-42.86%Miss-
    Dec 16
    Reported Mar 9
    		$0.19$0.20-5.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio50.17EV/EBITDA9.64x
    Price/FCF9.99xFCF Yield10.01%
    Profitability
    Profit Margin-2.63%Operating Margin13.70%
    ROE2.32%ROIC5.66%
    Financial Health
    Debt/Equity2.25xInterest CoverageN/A
    Current Ratio1.95xQuick Ratio1.78x
    Trading Statistics
    Beta1.91Avg Volume2.10M
    52-Week High$23.4452-Week Low$11.41

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.72
    SMA 20$13.97
    SMA 50$14.26
    SMA 200$14.46
    EMA 10$13.97
    EMA 20$13.99
    EMA 50$14.26
    EMA 200$15.25

    MACD

    Line: -0.08Signal: -0.15Hist: 0.08

    ADX

    ADX: 13.6+DI: 29.8-DI: 16.1

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down32.0
    PSAR$15.17

    Bollinger Bands

    Upper Band$15.27
    Lower Band$12.68
    %B Position1851%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    55.5

    Momentum Oscillators

    Stoch %K51.9
    Stoch %D35.3
    Williams %R-13.5
    ROC (10d)1.0%
    Momentum0.14
    CCI (20d)79.8
    MFI (14d)51.5

    Volatility Measures

    ATR (14d)$0.64(4.4%)
    StdDev (20d)0.65
    Hist Vol73.5%(High)

    Volume Flow

    VWAP$14.53
    OBV12.6M
    AD Line-3.4M
    CMF (20d)0.056

    Volume Metrics

    Avg Vol (20d)2.1M
    Vol Ratio0.5x
    VWMA (20d)$14.22

    Pivot Points

    R3$15.12
    R2$14.72
    R1$14.48
    Pivot Point$14.08
    S1$13.84
    S2$13.44
    S3$13.20

    Advanced Oscillators

    TSI-2.89
    Ultimate Osc58.3
    KST-25.63

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$848.90M$810.90M$885.00M$821.50M$826.20M$776.00M$864.40M$770.40M$762.10M$717.40M$735.40M$674.10M
    Cost of Revenue$253.10M$247.40M$-176,400,000$242.80M$450.20M$498.00M$517.70M$478.00M$468.30M$458.10M$887.70M$195.00M
    Gross Profit$595.80M$563.50M$1.06B$578.70M$376.00M$278.00M$346.70M$292.40M$293.80M$259.30M$-152,300,000$479.10M
    Operating Expenses$493.70M$497.70M$951.20M$473.00M$264.30M$216.10M$219.60M$231.50M$209.00M$183.30M$-253,700,000$396.50M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$417.70M$419.60M$850.20M$384.30M$193.60M$131.30M$127.10M$120.20M$132.70M$115.80M$-345,600,000$329.00M
    Operating Income$102.10M$65.80M$110.20M$105.70M$111.70M$61.90M$127.10M$60.90M$84.80M$76.00M$101.40M$82.60M
    Interest Income$-69,800,000$-69,100,000$-67,600,000$-74,900,000$-67,900,000$-62,200,000$-52,900,000$-50,000,000$-51,500,000$-47,300,000$-48,700,000$-49,800,000
    Interest Expense$69.80M$69.10M$67.60M$74.90M$67.90M$62.20M$52.90M$50.00M$51.50M$47.30M$48.70M$49.80M
    Income Before Tax$32.30M$-3,300,000$42.60M$30.80M$43.80M$-300,000$74.20M$10.90M$33.30M$28.70M$52.70M$32.80M
    Income Tax Expense$2.60M$-1,200,000$13.60M$5.50M$-1,100,000$0$120.80M$4.50M$4.90M$4.40M$6.00M$3.10M
    Net Income$29.70M$-2,100,000$29.00M$25.30M$44.90M$-300,000$-46,600,000$6.40M$28.40M$24.30M$46.70M$29.70M
    EBITDA$141.40M$104.30M$170.10M$145.20M$152.00M$98.20M$161.00M$111.10M$119.60M$109.70M$132.50M$111.50M
    EBIT$102.10M$65.80M$110.20M$105.70M$111.70M$61.90M$127.10M$60.90M$84.80M$76.00M$101.40M$82.60M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SGRY

    News

    Surgery Partners stock rises 2.34 percent to EUR 13.10

    Surgery Partners stock increased by 2.34 percent to EUR 13.10 on October 15, 2026. Cantor Fitzgerald maintained an Overweight rating and an USD 18.00 price target for the company. Despite reporting a loss in adjusted...

    ad-hoc-news.de•10/15/26•Bullish

    Larry Robbins Opens New Position in Surgery Partners Inc (SGRY) -- Shares Look 39% Undervalued on GF Value

    Larry Robbins of Glenview Capital Management has opened a new position in Surgery Partners Inc (SGRY), acquiring over 7 million shares...

    GuruFocus•10/15/26•Neutral

    San Antonio spine clinic says would-be buyer used deal talks to poach doctors

    South Texas Spinal Clinic has filed a lawsuit against Surgery Partners Inc., alleging the company used acquisition talks to access confidential information and then poached its top doctors to establish a competing...

    San Antonio Express-News•10/14/26•Bearish

    A passive holder reports shared voting power over 7.02M Surgery Partners (SGRY) shares.

    Glenview Capital Management, LLC and Larry Robbins have reported shared beneficial ownership of 7,023,338 shares of Surgery Partners, Inc. (SGRY)...

    Stock Titan•10/13/26•Neutral

    How Declining Sales At Surgery Partners (SGRY) Has Changed Its Investment Story

    Surgery Partners (SGRY) is facing challenges due to declining sales, rising interest costs on floating-rate debt...

    Simply Wall Street•10/12/26•Somewhat-Bearish

    SGRY Valuation and Fair Value

    P/E
    50.2x
    Forward P/E
    18.9x
    EV/EBITDA
    9.6x
    P/FCF
    10.0x
    PEG
    1.7x
    P/B
    1.1x
    See GNG's fair value

    SGRY Profitability: Margins, ROIC and FCF

    Gross margin
    83.2%
    Operating margin
    13.7%
    Net margin
    -2.6%
    ROIC
    5.7%
    ROE
    2.3%
    FCF margin
    5.6%
    FCF yield
    10.0%

    SGRY Competitors

    CompanyTicker
    UroGen Pharma LtdURGN
    Mineralys Therapeutics, Inc. Common StockMLYS
    Schrodinger IncSDGR
    Galapagos NV ADRGLPG
    BioLife Solutions IncBLFS
    Xeris Pharmaceuticals IncXERS
    LeMaitre Vascular IncLMAT
    Sarepta Therapeutics IncSRPT

    Sector: Healthcare

    SGRY Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    1
    Buy
    8
    Hold
    3
    Sell
    0
    Strong Sell
    0

    SGRY Bull Case vs Bear Case

    Bull case

    • 75.0% of SGRY's analyst ratings are Buy or Strong Buy.

    Bear case

    • SGRY trades at 50.2x trailing earnings.
    • SGRY has a -2.6% net profit margin.
    • SGRY has a debt-to-equity ratio of 2.2x.

    SGRY Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    40.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.12
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About SGRY

    Does SGRY pay dividends?

    Surgery Partners Inc (SGRY) does not currently pay a regular dividend.

    What is SGRY's P/E ratio?

    Surgery Partners Inc has a price-to-earnings (P/E) ratio of 50.17.

    What is SGRY's market cap?

    Surgery Partners Inc (SGRY) has a market capitalization of $1.86B with a current stock price of $14.55.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In